Dendritic cell inhibition correlates with survival of colorectal cancer patients on bevacizumab treatment

We demonstrated that dendritic cell (DC) inhibition by tumor-conditioned media in the presence or absence of bevacizumab correlates with colorectal cancer patient survival. Monitoring the influence of the tumor microenvironment on infiltrating immune cells may offer an avenue for the discovery of bi...

Descripción completa

Detalles Bibliográficos
Autores principales: Michielsen, Adriana J., Ryan, Elizabeth J., O’Sullivan, Jacintha N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2012
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518533/
https://www.ncbi.nlm.nih.gov/pubmed/23243624
http://dx.doi.org/10.4161/onci.21318
_version_ 1782252570997161984
author Michielsen, Adriana J.
Ryan, Elizabeth J.
O’Sullivan, Jacintha N.
author_facet Michielsen, Adriana J.
Ryan, Elizabeth J.
O’Sullivan, Jacintha N.
author_sort Michielsen, Adriana J.
collection PubMed
description We demonstrated that dendritic cell (DC) inhibition by tumor-conditioned media in the presence or absence of bevacizumab correlates with colorectal cancer patient survival. Monitoring the influence of the tumor microenvironment on infiltrating immune cells may offer an avenue for the discovery of biomarkers to guide the use of bevacizumab.
format Online
Article
Text
id pubmed-3518533
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-35185332012-12-14 Dendritic cell inhibition correlates with survival of colorectal cancer patients on bevacizumab treatment Michielsen, Adriana J. Ryan, Elizabeth J. O’Sullivan, Jacintha N. Oncoimmunology Author's View We demonstrated that dendritic cell (DC) inhibition by tumor-conditioned media in the presence or absence of bevacizumab correlates with colorectal cancer patient survival. Monitoring the influence of the tumor microenvironment on infiltrating immune cells may offer an avenue for the discovery of biomarkers to guide the use of bevacizumab. Landes Bioscience 2012-11-01 /pmc/articles/PMC3518533/ /pubmed/23243624 http://dx.doi.org/10.4161/onci.21318 Text en Copyright © 2012 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Michielsen, Adriana J.
Ryan, Elizabeth J.
O’Sullivan, Jacintha N.
Dendritic cell inhibition correlates with survival of colorectal cancer patients on bevacizumab treatment
title Dendritic cell inhibition correlates with survival of colorectal cancer patients on bevacizumab treatment
title_full Dendritic cell inhibition correlates with survival of colorectal cancer patients on bevacizumab treatment
title_fullStr Dendritic cell inhibition correlates with survival of colorectal cancer patients on bevacizumab treatment
title_full_unstemmed Dendritic cell inhibition correlates with survival of colorectal cancer patients on bevacizumab treatment
title_short Dendritic cell inhibition correlates with survival of colorectal cancer patients on bevacizumab treatment
title_sort dendritic cell inhibition correlates with survival of colorectal cancer patients on bevacizumab treatment
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518533/
https://www.ncbi.nlm.nih.gov/pubmed/23243624
http://dx.doi.org/10.4161/onci.21318
work_keys_str_mv AT michielsenadrianaj dendriticcellinhibitioncorrelateswithsurvivalofcolorectalcancerpatientsonbevacizumabtreatment
AT ryanelizabethj dendriticcellinhibitioncorrelateswithsurvivalofcolorectalcancerpatientsonbevacizumabtreatment
AT osullivanjacinthan dendriticcellinhibitioncorrelateswithsurvivalofcolorectalcancerpatientsonbevacizumabtreatment

Ejemplares similares